Epidermal growth factor has been demonstrated to enhance ovarian epithelial cell proliferation, facilitate EMT, elevate cancer cell invasiveness and drug resistance, and negatively impact patient differentiation and prognosis (Rodriguez et al., 1991; Grassi et al., 2017; Oh et al., 2014). The gene discussed is EGF; the disease is cancer.